<p>有时，跳入生物科技等行业的最佳方式是跟随热门交易。尽管这可能违反了避免炒作周期和害怕错过的常见建议，但查看哪些生物科技股票正在经历最高的 24 小时交易量可以快速了解是哪些催化剂正在推动投资者进入该行业。</p>
<p>这是因为生物科技行业在估计患者人口规模来预测未来药品产品或治疗需求方面具有独特性。例如，旨在治疗或预防病毒的药物具有无限的收入潜力，而治疗遗传性疾病的药物受到世界上患有该疾病的人数限制。</p>
<p>因此，投资者可以利用这些广泛的数字估计来评估生物科技股票的整体潜力，进行研究和组合选择。</p>
<h2>辉瑞（PFE）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：photobyphm / Shutterstock.com</p>
<p>在过去 24 小时内交易了 39,753,100 股的 <strong>辉瑞</strong>（纽约证券交易所：<strong>PFE</strong>）似乎重新成为焦点，因为它目前是交易量最大的生物科技股票。投资者的兴奋可能是因为辉瑞第二季度的收入大幅超出先前预期，公司提高了全年展望。即使在这个药品制造商正努力削减运营成本的时候，这一点也是如此，因为人们担心其新冠疫情产品将不再在市场上具备竞争力。</p>
<p>目前，公司的许多财务增长主要来自收购的药物和最近推出的治疗方案，成功抵消了新冠疫情产品需求下降。这突显了投资于像辉瑞这样的大型生物科技公司的现实，即公司既有资源又有规模，可以持续在市场上创造机会。因此，PFE 股票是当今交易中最热门的生物科技股票之一。</p>
<h2>默克（MRK）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Shutterstock</p>
<p>另一方面，<strong>默克</strong>（纽约证券交易所：<strong>MRK</strong>）在第二季度财报公布后，股价下跌，尽管财务指标相对稳定。在过去 24 小时内交易了 14,117,400 股，默克的投资者要么是在恐慌中抛售，要么是在买入低点。但股票的长期动态可能正在发生变化。</p>
<p>这是因为公司的一款关键突破性人乳头瘤病毒（HPV）疫苗在其关键的中国市场需求开始下滑。这种名为 Gardasil 的药物是默克过去几年的主要收入来源，但如果公司在海外扩大采用困难，销售可能会停滞。</p>
<p>此外，默克面临着其畅销癌症药物 Keytruda 之一的专利在 2028 年到期。尽管这还有几年的时间，但这意味着 MRK 一直享有的 Keytruda 患者群体无竞争环境将消失，最终影响价格和销售。虽然这对 MRK 投资者来说是一种损失，但更便宜的癌症药物对患者来说总是一种胜利。</p>
<h2>治疗药物（TEVA）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Jonathan Weiss / Shutterstock</p>
<p>在过去 24 小时内交易了 15,705,600 股的 <strong>治疗药物</strong>（纽约证券交易所：<strong>TEVA</strong>）可能意味着公司在制药领域的综合方法取得了成功。该公司悄悄积累了全球最大的 3500 种不同产品的仿制药组合。它现在为全球 58 个国家的患者提供服务，全球近 2 亿人每天服用治疗药物。</p>
<p>因此，治疗药物最大的资产是时间，因为随着品牌药物随着时间失去专利保护，公司将继续获得新的仿制药配方。对于投资者来说，这意味着今天在治疗药物中的早期位置可能会在未来转化为一个利润丰厚的持有，当许多已经最有效的配方完全成为仿制药并对广大人群可负担时。</p>
<p>考虑到这种潜在发展轨迹和其成功的第二季度财务增长，TEVA 股票可能会继续是市场上最受欢迎的生物科技股票之一。</p>
<p>_在发布日期，Viktor Zarev 在本文提到的证券中没有（直接或间接）任何头寸。本文中表达的观点属于作者，遵守 InvestorPlace.com 的发布指南。</p>
<p>_在发布日期，负责编辑在本文提到的证券中没有（直接或间接）任何头寸。</p>
<p>Viktor Zarev 是一位科学家、研究员和作家，专门通过对准确性和理解的奉献来解释技术股票的复杂世界。</p>
<p>生物科技、医疗保健</p>

辉瑞

默克

<p>目前最热门的生物科技股票是辉瑞（PFE）、默克（MRK）和特瓦制药（TEVA）。由于强劲的第二季度收入和积极的前景，辉瑞的股票交易量较高。默克的股票面临着挑战，因为其宫颈癌疫苗需求下降，且其癌症药物即将面临专利到期。特瓦制药在其仿制药产品组合方面取得成功，并预计在市场上保持受欢迎程度</p>

<p>Sometimes the best way to jump into an industry like biotech is to follow the popular trades. Though that may go against the common advice of avoiding hype cycles and the fear of missing out, seeing which biotech stocks are experiencing the highest 24-hour trading volumes can be a quick way to learn which catalysts are driving investors to the industry.</p>
<div class="lb-trans"><p>有时，跳入生物科技等行业的最佳方式是跟随热门交易。尽管这可能违反了避免炒作周期和害怕错过的常见建议，但查看哪些生物科技股票正在经历最高的 24 小时交易量可以快速了解是哪些催化剂正在推动投资者进入该行业。</p>
</div><p>That’s because the biotech industry is unique in its ability to forecast demand for a future drug product or treatment by estimating the size of a patient population. For example, drugs intended to treat or prevent viruses have limitless revenue potential while drugs that treat hereditary or genetic diseases are constrained in sales by the number of people in the world born with the disease.</p>
<div class="lb-trans"><p>这是因为生物科技行业在估计患者人口规模来预测未来药品产品或治疗需求方面具有独特性。例如，旨在治疗或预防病毒的药物具有无限的收入潜力，而治疗遗传性疾病的药物受到世界上患有该疾病的人数限制。</p>
</div><p>As such, investors can use these kinds of broad numerical estimates to gauge the overall potential of biotech stocks for research and portfolio selection.</p>
<div class="lb-trans"><p>因此，投资者可以利用这些广泛的数字估计来评估生物科技股票的整体潜力，进行研究和组合选择。</p>
</div><h2>Pfizer (PFE)</h2>
<div class="lb-trans"><h2>辉瑞（PFE）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: photobyphm / Shutterstock.com</p>
<div class="lb-trans"><p>来源：photobyphm / Shutterstock.com</p>
</div><p>With 39,753,100 shares trading in the last 24 hours, <strong>Pfizer</strong>(NYSE:<strong>PFE</strong>) seems to be back in the spotlight as it is currently the most traded biotech stock by volume. The investor excitement likely comes as a result of Pfizer’s second-quarter revenue handily exceeding previous expectations as the company raises its full-year outlook. This comes even at a time when the drugmaker is working to cut operational costs amid worries its Covid-19 products will no longer be relevant in the market.</p>
<div class="lb-trans"><p>在过去 24 小时内交易了 39,753,100 股的 <strong>辉瑞</strong>（纽约证券交易所：<strong>PFE</strong>）似乎重新成为焦点，因为它目前是交易量最大的生物科技股票。投资者的兴奋可能是因为辉瑞第二季度的收入大幅超出先前预期，公司提高了全年展望。即使在这个药品制造商正努力削减运营成本的时候，这一点也是如此，因为人们担心其新冠疫情产品将不再在市场上具备竞争力。</p>
</div><p>Currently, much of the company’s financial growth stems from acquired drugs and more recently launched treatments which have successfully offset the dip in Covid-19 product demand. This highlights the reality of investing in a large biotech corporation like Pfizer, which is that the company has both the resources and the mass to consistently create its opportunities in the market. As a result, PFE stock is among the hottest biotech stocks trading today.</p>
<div class="lb-trans"><p>目前，公司的许多财务增长主要来自收购的药物和最近推出的治疗方案，成功抵消了新冠疫情产品需求下降。这突显了投资于像辉瑞这样的大型生物科技公司的现实，即公司既有资源又有规模，可以持续在市场上创造机会。因此，PFE 股票是当今交易中最热门的生物科技股票之一。</p>
</div><h2>Merck (MRK)</h2>
<div class="lb-trans"><h2>默克（MRK）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>来源：Shutterstock</p>
</div><p>On the other side of the investing coin, <strong>Merck</strong>(NYSE:<strong>MRK</strong>) saw shares fall following its second-quarter earnings report, despite relatively steady financial metrics. With 14,117,400 shares moving in the last 24 hours, Merck investors are either selling in response to panic or buying the dip. But the long-term dynamics for the stock could be changing regardless.</p>
<div class="lb-trans"><p>另一方面，<strong>默克</strong>（纽约证券交易所：<strong>MRK</strong>）在第二季度财报公布后，股价下跌，尽管财务指标相对稳定。在过去 24 小时内交易了 14,117,400 股，默克的投资者要么是在恐慌中抛售，要么是在买入低点。但股票的长期动态可能正在发生变化。</p>
</div><p>That’s because one of the company’s key breakthrough vaccines for human papillomavirus (HPV) has seen demand begin to slip in its critical Chinese market. The drug, known as Gardasil, has been one of Merck’s main revenue drivers over the last few years, but should the company struggle to expand its adoption abroad, sales will likely stagnate.</p>
<div class="lb-trans"><p>这是因为公司的一款关键突破性人乳头瘤病毒（HPV）疫苗在其关键的中国市场需求开始下滑。这种名为 Gardasil 的药物是默克过去几年的主要收入来源，但如果公司在海外扩大采用困难，销售可能会停滞。</p>
</div><p>Beyond this, Merck faces the patent expiration of one of its best-selling cancer drugs, Keytruda, in 2028. While that’s still a handful of years away, it means the competition-free environment MRK has enjoyed for Keytruda’s patient population will vanish, ultimately impacting price and sales. While it’s a loss for MRK investors, cheaper cancer drugs are always a win for patients.</p>
<div class="lb-trans"><p>此外，默克面临着其畅销癌症药物 Keytruda 之一的专利在 2028 年到期。尽管这还有几年的时间，但这意味着 MRK 一直享有的 Keytruda 患者群体无竞争环境将消失，最终影响价格和销售。虽然这对 MRK 投资者来说是一种损失，但更便宜的癌症药物对患者来说总是一种胜利。</p>
</div><h2>Teva Pharmaceuticals (TEVA)</h2>
<div class="lb-trans"><h2>治疗药物（TEVA）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Jonathan Weiss / Shutterstock</p>
<div class="lb-trans"><p>来源：Jonathan Weiss / Shutterstock</p>
</div><p>Seeing 15,705,600 shares of <strong>Teva Pharmaceuticals</strong>(NYSE:<strong>TEVA</strong>) trade in the past 24 hours likely means the company’s generalist approach to the pharmaceutical sector is succeeding. The company has quietly amassed the world’s largest generic drug portfolio of 3,500 different products. It now serves patients in over 58 countries, with nearly 200 million people around the globe taking Teva medicine daily.</p>
<div class="lb-trans"><p>在过去 24 小时内交易了 15,705,600 股的 <strong>治疗药物</strong>（纽约证券交易所：<strong>TEVA</strong>）可能意味着公司在制药领域的综合方法取得了成功。该公司悄悄积累了全球最大的 3500 种不同产品的仿制药组合。它现在为全球 58 个国家的患者提供服务，全球近 2 亿人每天服用治疗药物。</p>
</div><p>Thus, Teva’s greatest asset is time, as the company will only continue to acquire new generic drug recipes as brand-name drugs lose their patent protection over time. For investors, this means an early position in Teva today could translate to a lucrative holding far into the future when many of the already most effective formulas are fully generic and affordable to vast population groups.</p>
<div class="lb-trans"><p>因此，治疗药物最大的资产是时间，因为随着品牌药物随着时间失去专利保护，公司将继续获得新的仿制药配方。对于投资者来说，这意味着今天在治疗药物中的早期位置可能会在未来转化为一个利润丰厚的持有，当许多已经最有效的配方完全成为仿制药并对广大人群可负担时。</p>
</div><p>With this potential trajectory and its successful second-quarter financial growth, TEVA stock will likely remain among the most popularly traded biotech stocks on the market.</p>
<div class="lb-trans"><p>考虑到这种潜在发展轨迹和其成功的第二季度财务增长，TEVA 股票可能会继续是市场上最受欢迎的生物科技股票之一。</p>
</div><p><em>On the date of publication, Viktor Zarev did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines</em> <em>.</em></p>
<div class="lb-trans"><p>_在发布日期，Viktor Zarev 在本文提到的证券中没有（直接或间接）任何头寸。本文中表达的观点属于作者，遵守 InvestorPlace.com 的发布指南。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>_在发布日期，负责编辑在本文提到的证券中没有（直接或间接）任何头寸。</p>
</div><p>Viktor Zarev is a scientist, researcher, and writer specializing in explaining the complex world of technology stocks through dedication to accuracy and understanding.</p>
<div class="lb-trans"><p>Viktor Zarev 是一位科学家、研究员和作家，专门通过对准确性和理解的奉献来解释技术股票的复杂世界。</p>
</div><p>Biotech, Healthcare</p>
<div class="lb-trans"><p>生物科技、医疗保健</p>
</div>

What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.

- 达到生物科技行业的最佳途径之一是关注热门交易。尽管这可能违背避免炒作周期和错失机会的常见建议，但查看哪些生物科技股票在过去 24 小时内交易量最高，可以快速了解推动投资者进入该行业的催化剂。
- 生物科技行业独特之处在于通过估计患者人群规模来预测未来药品或治疗的需求。例如，旨在治疗或预防病毒的药物具有无限的收入潜力，而治疗遗传疾病的药物受到世界上患有该疾病的人数限制。
- 投资者可以利用这些广泛的数字估计来评估生物科技股票的整体潜力，用于研究和组合选择。

目前最热门的生物科技股票有哪些？3 个顶级推荐